A
18.24
-0.60 (-3.18%)
| Previous Close | 18.84 |
| Open | 17.87 |
| Volume | 319,211 |
| Avg. Volume (3M) | 1,632,845 |
| Market Cap | 964,950,464 |
| Price / Sales | 5.20 |
| Price / Book | 15.02 |
| 52 Weeks Range |
| Profit Margin | 16,556.01% |
| Operating Margin (TTM) | -11,408.39% |
| Diluted EPS (TTM) | 118.98 |
| Quarterly Revenue Growth (YOY) | -66.40% |
| Total Debt/Equity (MRQ) | 0.65% |
| Current Ratio (MRQ) | 22.61 |
| Operating Cash Flow (TTM) | -52.31 M |
| Levered Free Cash Flow (TTM) | -238.14 M |
| Return on Assets (TTM) | -23.98% |
| Return on Equity (TTM) | 678.24% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Avalo Therapeutics, Inc. | Mixed | Bullish |
AIStockmoo Score
-1.4
| Analyst Consensus | NA |
| Insider Activity | -1.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -3.0 |
| Average | -1.38 |
|
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo’s pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 6.39% |
| % Held by Institutions | 76.24% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Tcg Crossover Management, Llc | 31 Mar 2026 | 738,383 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| DOYLE MITTIE | - | 19.50 | -1,000 | -19,500 |
| Aggregate Net Quantity | -1,000 | |||
| Aggregate Net Value ($) | -19,500 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 19.50 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| DOYLE MITTIE | Officer | 27 Jul 2026 | Automatic sell (-) | 1,000 | 19.50 | 19,500 |
| DOYLE MITTIE | Officer | 27 Jul 2026 | Option execute | 1,000 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |